Ypsomed announced that it launched YpsoLoop, its first autoinjector platform designed for circularity. The Swiss drug delivery device maker says the two new 1 mL and 2.25 mL platforms enable material recovery. Their design enables automated disassembly and efficient recycling while offering the convenience of a pre-filled, two-step autoinjector. Ypsomed said the YpsoLoop platform integrates […]
Auto-injectors
Analysts label Embecta ‘undervalued’ and poised for growth
BTIG analysts maintain a “Buy” rating for Embecta (Nasdaq:EMBC) after meetings with company officials highlighted plans for growth. Marie Thibault, Sam Eiber and Alexandra Pang hosted Embecta CEO Devdatt Kurdikar and Head of Investor Relations Pravesh Khandelwal this week. Following the in-person and virtual meetings, the analysts maintain confidence in the former BD Diabetes unit’s […]
Ypsomed gets FDA nod for digital add-on for autoinjectors
Ypsomed announced that the FDA granted 510(k) clearance for SmartPilot, a digital connectivity add-on for its Ypsomate autoinjectors. The device transforms the YpsoMate into a connected system that automatically captures and transmits injection data. Ypsomed said this marks an important step toward digital health solutions that offer deeper insight into therapy use. The digital add-on […]
MannKind enters cardiometabolic, lung disease drug delivery space with scPharmaceuticals acquisition
MannKind (Nasdaq:MNKD) announced today that it entered into a definitive agreement under which it acquires scPharmaceuticals. The proposed acquisition could deliver MannKind’s strategic expansion into cardiorenal medicine. Danbury, Connecticut-based MannKind already offers inhaled insulin therapy. scPharmaceuticals, meanwhile, markets Furoscix, an FDA-approved on-body unfuser delivering furosemide. Furosemide currently serves as the standard for treating fluid overload […]
Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China
Ypsomed announced today that Chinese regulatory authorities approved the a dual GCP/GLP-1 drug delivered using its auto-injector. The Chinese National Medical Products Administration (NMPA) approved Maxdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, developed by Innovent Biologics. It treats people with obesity through delivery with an YpsoMate 1.0 auto-injector variant. YpsoMate, a user-friendly […]
Embecta eyes shift from insulin delivery to broader medical supplies focus
Embecta (Nasdaq:EMBC) today revealed its phased plan to create value and shift priorities toward broader medical applications. The pure-play diabetes technology company has endured ups and downs since its 2022 spin-off from BD. That includes an FDA approval for a disposable insulin patch pump system in September 2024, only to be followed by the discontinuation […]
Embecta to undergo further restructuring, lowers guidance amid tariff impact
Embecta (Nasdaq:EMBC) stock was down today after news of restructuring and mixed second-quarter results. Shares of EMBC were down more than 8% to $12.12 apiece near the close of trading today. While the company continues to work through the discontinuation of its insulin patch pump program — the plan for which it says is substantially […]
IDE Group launches ophthalmic auto-injector
IDE Group recently unveiled OKO, its new ophthalmic auto-injector for improving drug delivery precision and efficiency. The company says OKO addresses critical unmet needs in ophthalmology. It aims to improve precision, procedural efficiency and patient safety compared to existing adapted injection methods. Currently, intravitreal injections — essential injections for treating retinal diseases like wet age-related […]
Analysts say Embecta is ‘heading in the right direction’ following patch pump discontinuation
Analysts called a recent stock sell-off at Embecta (Nasdaq:EMBC) “unwarranted” and believe the company is moving in the right direction despite recent challenges. Late last year, Embecta filed with the state of Massachusetts to confirm a workforce reduction affecting 118 employees. This related to the company’s plans to discontinue its insulin patch pump program and restructure. […]
Ypsomed, BD collab on self-injection systems for high-viscosity biologics
BD (NYSE:BDX) and Ypsomed today announced a strategic collaboration to advance self-injection solutions for high-viscosity biologic drugs. In a joint project, the companies pre-assessed and streamlined the integration of the BD Neopak XtraFlow glass prefillable syringe with the Ypsomed YpsoMate 2.25 auto-injector platform. They aim to address current limitations by enabling the delivery of higher-viscosity […]
